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Russell's viper venom PLA2An acidic phospholipase A2 (RVVA-PLA2-I) puriﬁed from Daboia russelli venom demonstrated dose-dependent
catalytic, mitochondrial and erythrocyte membrane damaging activities. RVVA-PLA2-I was non‐lethal to mice
at the tested dose, however, it affected the different organs of mice particularly the liver and cardiac tissues as
deduced from the enzymatic activities measured in mice serum after injection of this PLA2 enzyme. RVVA-
PLA2-I preferentially hydrolyzed phospholipids (phosphatidylcholine) of erythrocyte membrane compared to
the liver mitochondrial membrane. Interestingly, RVVA-PLA2-I failed to hydrolyze membrane phospholipids of
HT-29 (colon adenocarcinoma) cells, which contain an abundance of phosphatidylcholine in its outer mem-
brane,within 24 h of incubation. The gas-chromatographic (GC) analysis of saturated/unsaturated fatty acids' re-
lease patterns from intact mitochondrial and erythrocyte membranes after the addition of RVVA-PLA2-I showed
a distinctly different result. The results are certainly a reﬂection of differences in the outer membrane phospho-
lipid composition of tested membranes owing to which they are hydrolyzed by the venom PLA2s to a different
extent. The chemical modiﬁcation of essential amino acids present in the active site, neutralization study with
polyvalent antivenom and heat-inactivation of RVVA-PLA2-I suggested the correlation between catalytic and
membrane damaging activities of this PLA2 enzyme. Our study advocates that the presence of a large number
of PLA2-sensitive phospholipid domains/composition, rather than only the phosphatidylcholine (PC) content
of that particular membrane may determine the extent of membrane damage by a particular venom PLA2
enzyme.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Russell's viper (Daboia russelli) is regarded as one of the most
medically important venomous snakes in many South-east Asian
countries, including India [1]. Depending on the zoogeographic ori-
gins of Russell's vipers, their venom composition may vary, as a result
of which envenomation by this snake displays an intriguing variation
in the clinical manifestation [2,3].
Russell's viper venom is known to contain different isoforms of phos-
pholipase A2 (EC 3.1.1.4) that hydrolyzes glycerophospholipids at the
sn-2 position of the glycerol backbone releasing lysophospholipids and
fatty acids [4–6]. PLA2s from venoms, in addition to digestion of pray,
exhibit wide varieties of pharmacological effects such as neurotoxicity,DTT, Dithiothreitol; FA, Fatty
, Phosphatidylethanolamine;
; TLCK, N-α-p-tosyl-L-lysine
methyl ketone
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rights reserved.cardiotoxicity, myotoxicity, necrosis, anticoagulation, hypotension,
haemolysis, haemorrhage and oedema inducing activities [7]. Differ-
ent isoforms of PLA2, which may be acidic, basic or, neutral in nature
on the basis of their elution proﬁle from ion-exchange columns, can
exist in a single venom [3], and each PLA2 may exert different patho-
physiological effects by awide range of mechanisms in snakebite vic-
tims [2,3,6]. Therefore, it remains a challenging task for the scientists to
elucidate the structure–function relationships of this class of protein.
Most of the toxic effects of snake venom PLA2 are dependent on
the hydrolysis of cellular or sub‐cellular membrane phospholipids,
and/or generation of phospholipid hydrolyzed breakdown products
which are themselves lytic and can cause considerable membrane
damage [7–9]. Kinetic studies of PLA2 in the scooting mode establish
that these enzymes bind to the intact membrane surface as a prelude
to loading of the active site with a single phospholipidmolecule, more
speciﬁcally they bind to the phosphatidylcholine (PC) present in the
outer leaﬂet of the membrane for the lipolysis reaction [5,10]. It is
now becoming apparent that the different isoforms of venom PLA2
can display dramatically different afﬁnities for biomembranes, com-
posed of different phospholipid polar head groups and fatty acyl
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[5,8,11]. This speciﬁcity of phospholipases has been extensively
used to explore the physical structure of phospholipids in biological
membranes [12]. It is exemplary to mention that only a few reports
on membrane hydrolyzing property of PLA2s from RVV are available
[13,14]. Therefore, more precise studies are necessary to advance
our understanding of the mechanism(s) of membrane damage and
subsequent toxicity of PLA2 enzymes from RVV.
Perusal of literature has showed that limited attempts have been
made to explore the biochemical and pharmacological properties of
acidic PLA2 from snake venom. Recently, we reported the puriﬁcation
and biochemical characterization of an acidic, strong anticoagulant
PLA2 (RVVA-PLA2-I) from Russell's viper venom [15]. In this study, we
are reporting the membrane damaging activity of RVVA-PLA2-I from
D. russelli venom. Further, our study provides an insight into the mem-
brane damaging activity of this acidic PLA2, and suggests that it has a
distinct preference for hydrolyzing speciﬁc phospholipid domain(s) in
intact mitochondrial and erythrocyte membranes, whereas its effect
on HT-29 adenocarcinoma cells are minimal, which may be due to the
absence of RVVA-PLA2-I-sensitive phospholipid domains in HT-29 cells.
2. Materials and methods
2.1. Materials
D. russelli venom was purchased from Calcutta Snake Park, Kolkata.
CM Sephadex C-50, DEAE Sephadex A-50 and Sephadex G-50 (ﬁne
grade) were obtained from Pharmacia Fine Chemicals, Sweden. All
other reagents of analytical grade were purchased from Sigma, India.
The human colon adenocarcinoma (HT-29) cell was procured from Na-
tional Centre for Cell Sciences (NCCS), Pune, India. The “In Vitro Toxicol-
ogy Assay Kit (XTT based)” was purchased from Sigma-Aldrich, India.
Polyvalent antivenom was purchased from Bharat Serum and Vaccines
Limited, Ambernath. The kits for estimation of total protein, triglycer-
ides, total cholesterol, urea, uric acid, serum glutamic oxaloacetic trans-
aminase (SGOT), and serum glutamic pyruvic transaminase (SGPT)
were procured from Coral Clinical Systems (Goa, India). The kits for
the measurement of serum levels of glucose, alkaline phosphatase
(ALP), and creatine phosphokinase (CPK-MB) were obtained from
Erba Diagnostics (Mumbai, India) whereas the kit for estimation of
serum lactate dehydrogenase (LDH)was obtained from Fisher scientiﬁc
(Mumbai, India). The animal food was obtained from Pranav Agrotech,
Delhi, India. The RVVA-PLA2-I, an acidic PLA2, was puriﬁed from crude
RVV as described previously [15].
2.2. Methods
2.2.1. Phospholipase A2 activity
For the screening purpose, PLA2 activity of crude RVV and RVVA-
PLA2-I was determined as described by Doley and Mukherjee [16]
using egg yolk phospholipids as substrate. One unit of PLA2 activity
was deﬁned as the amount of protein which produces a decrease in
0.01 absorbance in 10 min at 740 nm. To determine the substrate
speciﬁcity and phospholipid head-group preference of RVVA-PLA2-I
different commercially available phospholipids such as PC, PS and
PE at a ﬁnal concentration 1 mM were incubated with 100 nM en-
zyme at 37 °C for desired time periods and PLA2 activity was assayed
by titrametric method using palmitic acid as fatty acid standard [5].
2.2.2. Membrane damaging activity
Isolation of mitochondria from fresh chicken liver at 4 °C was
described previously [5]. For the assay of RVVA-PLA2-I induced mito-
chondrial swelling and membrane damage, mitochondrial suspension
containing 100 mg equivalent of mitochondria (mitochondria obtained
from 100 mg wet weight of tissues) in 2.0 ml of assay buffer (20 mM
Tris–HCl, pH 7.4, containing 0.3 M sucrose) were incubated with100 nM of RVVA-PLA2-I, either in the presence or absence of 2 mM
Ca2+, at 37 °C for the desired time period. Mitochondrial swelling was
followed spectrophotometrically by the decrease in absorbance at
520 nm for 30 min [5]. One unit of swelling is deﬁned as a decrease in
0.01 absorbance per min of mitochondrial suspension at 520 nm by
added RVVA-PLA2-I (100 nM) as compared to control (mitochondrial
suspension without RVVA-PLA2-I) under the experimental condition.
The basic test system without added RVVA-PLA2-I was served as a con-
trol. Qualitative and quantitative analyses of liberated fatty acids and
lysophospholipids from the mitochondrial membranes due to the
action of RVVA-PLA2-I were performed by gas-chromatography as
described below. A control was also set up where the mitochondria
were treated under the identical condition except the addition of
RVVA-PLA2-I.
For the estimation of RVVA-PLA2-I induced haemolysis and eryth-
rocyte phospholipid hydrolysis, goat blood was collected in 3.8%
tri-sodium citrate and erythrocytes were separated by centrifuging the
citrated blood at 1000×g for 15 min, washed twice with isotonic
K-phosphate buffer, pH 7.4 and suspended in the same buffer at a con-
centration of 5% (v/v). RVVA-PLA2-I at a ﬁnal concentration of 100 nM
was added to 3.0 ml of the above said erythrocyte suspension and the
haemolysis and erythrocyte phospholipid hydrolysis by RVVA-PLA2-I
were measured as described previously [5,8]. For determining the
role of exogenously added phospholipids in haemolytic activity (indi-
rect haemolytic activity), either PC (ﬁnal concentration of 1 mM) or
egg yolk phospholipids (0.1% v/v) were added to the erythrocyte sus-
pension prior to the addition of RVVA-PLA2-I. The reaction was initi-
ated by the addition of PLA2 followed by measuring the haemolysis
as stated above [5]. For each of the experiment isotonic saline instead
of RVVA-PLA2-I was used as a control.
Erythrocytes or mitochondria, after treatment with RVVA-PLA2-I,
were centrifuged at 10,000×g and 1.0 ml of supernatant was used
for the extraction and quantiﬁcation of total lipid and fatty acids
from the reaction mixture [5]. For the estimation of phospholipids/
lysophospholipids released from the membrane, the total lipid
extracted from the supernatant was digested with concentrated
HNO3 in a Kjeldahl ﬂask until a white precipitate was formed and
then the liberated Pi was estimated calorimetrically as described by
Doley et al. [5].
To study the effect of heating on catalytic and membrane damaging
activities, RVVA-PLA2-I solution (100 nM) was heated at 75 °C for dif-
ferent time periods (5–60 min), cooled immediately in ice-bath and
then the required volume was withdrawn for the spectroﬂurometric
study, assay of catalytic and membrane damaging activities of this
enzyme.
2.2.3. Gas-chromatography analysis of liberated fatty acids frommembranes
The total lipid released from the membranes after the treatment of
RVVA-PLA2-I was extracted and from this total lipid, liberated fatty
acids were extracted and methylated as described by Mukherjee et
al. [11]. The dry sample (fatty acid methyl esters) was dissolved in a
minimum quantity of chloroform and analysed on a GC–MS (Varian
3800, Saturn 2000) system. The samples (1.0 μl) were injected
using a split ratio of 100:1 into a fused silica GC column CP-Sil 8 CB
low bleed (30 m×0.25 mm×0.25 μm) coupled with a CP-Sil 5 CB
low bleed/MS (30 m×0.25 mm×0.25 μm) column with helium as
the carrier gas. The systemwas equipped with ﬂame ionization detec-
tor. The initial oven temperature was 120 °C and a temperature
programme of 8 °C per min began at injection and continued to a
ﬁnal oven temperature of 270 °C, which was hold isothermal for
3 min. The injector port and detector temperature were set at
250 °C. The mass spectrometric data were acquired in electron ioni-
zation mode (70 eV). The unknownmethylated fatty acids were iden-
tiﬁed by matching both retention time and MS of the unknown
compound with those of authentic standards (Saturn 2000 MS li-
brary search). The fatty acids were quantitated by measuring and
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the GC chromatogram of standard (known) fatty acids.
2.2.4. Modiﬁcation and neutralization of RVVA-PLA2-I with inhibitors
and commercial antivenom
For RVVA-PLA2-I-inhibition study, different inhibitors such as TPCK,
TLCK, PMSF, p-BPB, EDTA, DTT, IAA, and commercial polyvalent anti-
venom raised in horse against crude RVV were pre-incubated with a
constant amount of RVVA-PLA2-I (100 nM) at 37 °C for 30 min [5,15].
The mixture was then assayed for the catalytic and membrane damag-
ing activities of the RVVA-PLA2-I in the corresponding assay system.
2.2.5. Enzyme immunoassay to determine the binding of RVVA-PLA2-I
with membranes
Supernatant obtained from the incubation of intact mitochondria
or erythrocytes with puriﬁed RVVA-PLA2-I (native, heated or chemi-
cally modiﬁed) at 4 °C for 30 min was tested for free (unbound)
toxin concentration by ELISA using horse polyclonal antibodies and
rabbit anti-horse IgG peroxidase conjugate [5]. A standard curve of
PLA2 was plotted by adding graded concentration of RVVA-PLA2-I
(30–200 nM per well) in the wells of the ELISA plate and the concen-
tration of unbound RVVA-PLA2-I was determined from this curve by
using an ELISA plate reader (Thermo Electron Corporation, Multiskan
ascent, Type 354). Each experiment was repeated thrice to assure the
reproducibility.
2.2.6. Measurement of interaction of RVVA-PLA2-I with PC
The dose-dependent interaction of PC with RVVA-PLA2-I was mea-
sured by using a ﬂuorescence spectrometer [15]. Brieﬂy, PC was
suspended in 20 mM Tris–HCl, pH 8.0 buffer at a ﬁnal concentration
of 0.1–1.0 mM and sonicated for about 5 min at 4 °C with a Labsonic®
M (Sartorius) sonicator. To this, 100 nM of RVVA-PLA2-I (dissolved in
20 mM Tris–HCl, pH 8.0) was mixed and ﬂuorescence spectra were
obtained at an excitation wavelength of 280 nm, excitation and emis-
sion slits of 5 nm (at room temperature ~23 °C). Wavelength shifts
were measured by taking the midpoint at two thirds the height of the
spectrum. The maximum ﬂuorescence of free protein (I0) was also
measured.
2.2.7. Cytotoxicity assay on tumour cells
Cytotoxicity was assessed on human adenocarcinoma tumour cell
line (HT29) as described by us with the following modiﬁcations [8].
Brieﬂy, human colon adenocarcinoma (HT-29) cells were maintained
in Dulbecco's Modiﬁed Eagle's medium (DMEM) supplemented with
10% foetal bovine serum (FBS), penicillin (50U ml−1), streptomycin
(50 mg ml−1) at 5% CO2 in a humidiﬁed incubator at 37 °C. For cytotox-
icity assays, 1×104 cells were seeded in 96-well plate and left overnight
for attachment. Then crude RVV (10 μg ml−1) or RVVA-PLA2-I
(10 μg ml−1 equivalent to 172 nM), diluted in DMEM media were
added to the cells and incubated for either 4 h or 24 h. Cell viability
was measured by using in vitro Toxicology Assay Kit (XTT based)
according to the manufacturer's protocol and the percentage viability
was calculated as the ratio of treated cells to the control (cells without
addition of CRVV/RVVA-PLA2-I) cells. Cells were also observed under
the inverted phase contrast microscope for any visible morphological
changes.
2.2.8. Determination of lethality and toxicity on mice
All the BALB/c mice, weighed between 20 and 30 g, were born in the
laboratory breeding colony of the Central Facility of Animal House,
Defence Research Laboratory, Tezpur, Assam and were pathogen free.
General conditions of captivity were maintained in simulated atmo-
spheric conditions of North East India (temperature 33–36 °C, relative
humidity≥75%).In captivity, seasonal variations of physiological func-
tions are entrained by altering six-month periods of summer like long
photoperiod (14 h of light/day). The general conditions of captivitywere applied as described above and animals were maintained in social
groups before and after experimenting. All experimenting protocols
using animalswere performed according to the “Principles of Laboratory
Animal care” (NIH publication 85-23, revised 1985) and approved by
the Institutional Animal Ethical Committee.
The acute toxicity was determined as per protocol of OECD/OCED
guidelines 425 [17]. For toxicity assessment of RVVA-PLA2-I-in ro-
dents, RVVA-PLA2-I (0.2 mg kg−1 body weight) dissolved in 0.1 ml
of PBS was injected intraperitoneally into a group of six BALB/c
mice. The mice were assigned as a control group (Group I, n=6)
and one RVVA-PLA2-I treated group (Group II, n=6). The animals
were observed at regular intervals for up to 48 h after the injection
for any behavioural changes viz., body weight, food and water intake,
faecal and urination, grip strength, ear twist, rectal temperature etc.,
effect on circulatory system, and/or death. Bleeding time along with
clotting time was also recorded before sacriﬁcing the animals. Control
animals (placebo) were injected with 0.1 ml of PBS only.
Frommice sacriﬁced after 48 h of injection, blood was collected im-
mediately by venipuncture and the serumused for the assay of different
parameters viz. total protein, glucose, cholesterol, triglycerides, uric
acid and urea levels as well as different enzymatic activities viz. LDH,
ALP (alkaline phosphatase), CPK (creatine phosphokinase), SGOT and
SGPT by using commercial kits following the instructions of manufac-
turers. To study the effect of RVVA-PLA2-I on blood cells, RBC and
WBC counts were done by an automatic cell counter (Automated
haematology cell counter —MS 4(s), Melet Schloesing Laboratories).
2.2.9. Statistical analysis
The statistical analysis of the data was done by Student's t test
using the software SigmaPlot 11.0 for windows (version 7.0). The
value of p≤0.05 was considered as signiﬁcant.
3. Results
3.1. Effect of RVVA-PLA2-I on membrane phospholipid hydrolysis
With an increase in incubation time of mitochondria with RVVA-
PLA2-I, a signiﬁcant damage to mitochondria was observed which was
further pronounced in the presence of Ca2+ (Table 1). A deeper insight
into the mode of attack of RVVA-PLA2-I on the mitochondrial mem-
brane was revealed by GC-analysis of liberated fatty acids which
showed that straight chain saturated fatty acids such as C16:0, C17:0,
C18:0, and C19:0 were the most prominent fatty acids released from the
membrane within the initial 30 min of attack by RVVA-PLA2-I (Fig. 1).
Further, with an increase in the incubation time of mitochondria with
the RVVA-PLA2-I, a corresponding increase in membrane phospholipid
hydrolysis was observed (Fig. 1).
The RVVA-PLA2-I at a concentration of 100 nM did not exert any
appreciable haemolytic activity directly on washed erythrocytes;
however, exogenous addition of egg yolk phospholipids (which is a
source of PC) to the erythrocyte suspension enhanced the haemolytic
activity of RVVA-PLA2-I to a signiﬁcant extent (Table 2). Either with
an increase in the concentration of RVVA-PLA2-I (data not shown)
or an increase in the incubation time of PLA2 with the erythrocytes
(Table 2), a concomitant enhancement in the release of fatty acids
and measured Pi from the erythrocyte membranes was observed. It
is worthy to mention that during the initial 30 min of attack,
haemolysis could not be detected although RVVA-PLA2-I was able to
release the FAs and lysophospholipids from the intact erythrocyte
membranes. In contrast, the addition of egg-yolk phospholipids to
the erythrocyte suspension resulted in the initiation of haemolysis
within 30 min of incubation, and after 120 min, about 47.6% of total
erythrocytes were haemolysed (Table 2).
The GC analysis of erythrocyte membrane phospholipid hydrolysis
by RVVA-PLA2-I had shown a speciﬁc preference for releasing the un-
saturated straight chain fatty acids such as fatty acids for example,
Table 1
RVVA-PLA2-I induced swelling and phospholipid hydrolysis of intact mitochondrial membrane either in the presence or in the absence of 2 mM Ca2+. About 100 mg equivalent of
mitochondria (mitochondria obtained from 100 mg wet weight of tissue) from chicken liver was incubated with 100 nM of RVVA-PLA2-I at 37 °C for different time periods. The
measured Pi value was obtained from acid treatment of a sample of the supernatant. Values are mean±S.D. of triplicate determinations.
Incubation time (min) Mitochondrial swelling (U/min)a Phospholipid hydrolysis Ratio of saturated/
unsaturated FA
μg FA released μg of measured Pi
−Ca2+ +Ca2+ −Ca2+ +Ca2+ −Ca2+ +Ca2+
0 (control) 0 0 0 0 0 0 0
15 550±2.5 700±1.1 132.9±0.9 159.5±0.5 15.7±2.6 17.0±1.5 5.1±0.5
30 900±1.2 1150±2.5 799.4±1.2 1019.1±1.3 77.8±1.9 85.0±1.2 7.1±0.2
60 1350±1.5 1650±0.5 1503.8±1.6 1954.9±1.8 126.5±1.3 163.4±2.2 8.9±0.8
a Mitochondrial swelling was measured spectrophotometrically and one unit of swelling is deﬁned as a decrease in 0.01 absorbance/min of mitochondrial suspension at 520 nm
by 100 nM of RVVA-PLA2-I.
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30 min of incubation. This result corroborates well with our previous
report showing preferential release of unsaturated fatty acids from
the erythrocyte membrane during the initial stage of attack by a
PLA2 (NK-PLA2-I) from N. kaouthia venom [18]. However, after
120 min of incubationof erythrocyteswith RVVA-PLA2-I, additional sat-
urated FAs of chain lengths C15:0, C16:0, C17:0, C19:0, C20:0, and C22:0, and
unsaturated fatty acid such as C18:03 were detected. Nevertheless, a
few saturated and unsaturated fatty acids (>C20) liberated from the
membrane due to action of RVVA-PLA2-I could not be identiﬁed
(Fig. 2). The TLC analysis of phospholipids and lysophospholipids re-
leased from the erythrocyte ormitochondrialmembrane after the treat-
ment with RVVA-PLA2-I demonstrated the release of most of the FAs
from the membrane PC pools (Supplementary Fig. S1).
A comparison of ratios of saturated/unsaturated fatty acids re-
leased from the intact mitochondrial membrane (Table 1) after the
addition of RVVA-PLA2-I suggested that the enzyme has a distinct
preference for hydrolyzing phospholipids containing saturated fattyFig 1. Kinetics of mitochondrial membrane phospholipid hydrolysis by RVVA-PLA2-I. Abou
weight of tissue) were incubated with 100 nM of RVVA-PLA2-I (in the presence of 2 mM
GC–MS as described in the text. A) control, B) 15 min, C) 30 min, and D) 60 min after incuacids at sn-2 position in mitochondrial membrane. But in sharp con-
trast, during the initial phase of attack, this acidic PLA2 prefers hy-
drolysis of unsaturated fatty acids in the erythrocyte membrane
(Table 2). Therefore, the ratio of saturated/unsaturated fatty acids re-
leased from the erythrocyte membrane was less than 1.0 for up to
30 min of incubation with RVVA-PLA2-I. Increase in incubation time
beyond 30 min resulted in a change in RVVA-PLA2-I induced fatty
acids' release pattern from the erythrocyte membrane owing to a
greater hydrolysis of phospholipids containing saturated fatty acids
compared to unsaturated fatty acids at sn-2 position (Table 2).
3.2. Effect of inhibitors and antivenom on catalytic and membrane
damaging activities
Different irreversible modiﬁers of serine residue viz. TPCK (inhibitor
of chymotrypsin like serine protease), TLCK (inhibitor of trypsin-like
serine protease) and PMSF (inhibitor of serine proteases) at 2.0 mM
concentration did not affect the catalytic and membrane damagingt 100 mg equivalents of liver mitochondria (mitochondria obtained from 100 mg wet
Ca2+) at 37 °C for different time periods. The liberated fatty acids were analysed by
bation of mitochondrial membranes with RVVA-PLA2-I.
Table 2
RVVA-PLA2-I induced haemolysis and phospholipid hydrolysis of goat washed erythrocytes. The 5% (v/v) erythrocyte suspension was incubated with 100 nM
of RVVA-PLA2-I at 37 °C and haemolysis (direct and indirect) and erythrocyte phospholipid hydrolysis were determined. Indirect phospholipid hydrolysis was
achieved in the presence of egg yolk phospholipids (which is a source of PC). The measured Pi value was obtained from acid treatment of a sample of the su-
pernatant. Values are mean±S.D. of triplicate determinations.
Incubation time (min) % haemolysis Phospholipid hydrolysis Ratio of saturated/unsaturated FA
Direct Indirect μg FA released μg of measured Pi
Control 0 0 0 0 0
15 min 0 0 202.5±2.1 28.4±0.9 0.68±0.3
30 min 0 34.5±0.45 1015.3±2.5 163.2±1.2 0.86±0.4
60 min 0.6±0.03 42.1±0.45 2045.1±1.4 253.2±1.7 1.64±0.8
120 min 1.9±0.09 47.6±0.12 2531.9±1.9 302.3±1.1 1.91±0.1
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we propose that serine residue perhaps does not have a contribution
to the above mentioned activities of RVVA-PLA2-I (Table 3). However,
the modiﬁcation of enzymewith pBPB, an inhibitor of histidine residue,
drastically reduced the catalytic as well as the membrane damaging ac-
tivities of RVVA-PLA2-I indicating a correlation between catalytic and
membrane damaging activities of this enzyme (Table 3). Furthermore,
as shown in Table 3, EDTA signiﬁcantly inhibited the catalytic andmem-
brane phospholipid hydrolyzing activity of RVVA-PLA2-I probably by
chelating the Ca2+ ion required for the enzymatic activity [15]. The
observed signiﬁcant reduction (37–44%) in catalytic and membrane
damaging activities of RVVA-PLA2-I post‐treatment with DTT under
the experimental condition was due to partial reduction of disulﬁde
bonds present in this PLA2molecule. Presence of 7–8 intra-molecular di-
sulﬁde bridges has been reported in PLA2 molecules from snake venom
[5–8]. Furthermore, IAA (a sulfhydryl-reactive alkylating reagent used to
modify the cysteine residue) at the tested concentrations inhibited the
catalytic and membrane damaging activities of RVVA-PLA2-I almost to
the same extent which may be due to the modiﬁcation of cysteineFig 2. Kinetics of erythrocyte membrane phospholipid hydrolysis by RVVA-PLA2-I. The 5% (v/
of 2 mM Ca2+) at 37 °C for different time periods. The liberated fatty acids were analysed by
incubation of erythrocyte membranes with RVVA-PLA2-I.residues of this PLA2 responsible for the intramolecular disulﬁde bond
formation (Table 3).
3.3. Binding with phospholipids
The spectroﬂurometric study revealed the concentration dependent
binding of PC with RVVA-PLA2-I (Supplementary Fig. S2). Binding ef-
ﬁciency of the heat-inactivated RVVA-PLA2-I had drastically reduced
(69%) compared to the PC binding potency of native RVVA-PLA2-I
(Table 3 and Supplementary Fig. S3).In the present study, RVVA-PLA2-I
showed equal binding afﬁnity for both mitochondrial and erythrocyte
membranes (data not shown). The membrane binding property of
heat-inactivated RVVA-PLA2-I, as evaluated by the ELISA experiment, re-
vealed the binding of about 65±2% (mean±S.D., n=3) of heated
RVVA-PLA2-I (heated for 60 min at 75 °C) to intact erythrocyte or mito-
chondrialmembranes as compared to 100%binding of native (unheated)
RVVA-PLA2-I. This suggested the partial loss of membrane binding prop-
erty of heat-inactivated enzyme. In contrast, histidine-modiﬁed RVVA-
PLA2-I was captured by intact erythrocytes and mitochondria to thev) erythrocyte suspension was incubated with 100 nM of RVVA-PLA2-I (in the presence
GC–MS as described in the text. A) control, B) 30 min, C) 60 min, and D) 120 min after
Table 3
Effects of heating, antivenom and inhibitors (at a ﬁnal concentration of 2 mM) on catalytic and membrane phospholipid hydrolytic activities of RVVA-PLA2-I
(100 nM). Values are mean±S. D. of triplicate determinations. MM: mitochondrial membrane, EM: erythrocyte membrane.
% residual activity Binding with PC (%)
PLA2 MM hydrolysis EM hydrolysis
Control 100 100 100 100
Chemicals/inhibitors 97.8±1.9 96.0±1.8 96.5±4.7 –
TPCK 94.9±1.7 97.2±1.9 100 –
TLCK 9.7±0.5 12.1±0.8 18.5±0.9 –
pBPB 97.6±1.8 97.7±1.8 95.2±1.7 97.0±1.3
PMSF 63.0±3.1 55.5±1.7 61.5±1.7 –
DTT 56.7±2.8 60.1±2.0 56.6±2.8 –
IAA 20.6±1.5 23.2±1.8 25.9±2.1 –
EDTA
Antigen: antivenom (w:w)
1:100 90.1±1.5 89.9±0.5 85.8±1.3 –
1:200 84.4±1.2 76.8±1.8 66.7±2.3 –
1:500 75.4±0.8 55.3±1.7 51.6±2.6 –
Heating at 75 °C
10 min 97.0±1.8 97.5±0.8 95.9±1.7 97.5±1.8
20 min 94.5±1.7 95.1±1.7 91.8±1.6 91.4±1.6
30 min 90.5±1.5 89.0±0.5 88.5±2.4 86.6±2.3
45 min 85.4±2.3 79.4±1.9 74.4±0.7 75.1±0.8
60 min 70.8±1.5 69.5±1.4 67.2±1.3 69.0±1.4
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modiﬁcation of histidine residue(s) of RVVA-PLA2-I did not affect its
membrane binding property (Table 3).
3.4. Cytotoxicity assay
The cytotoxicity assay showed that the RVVA-PLA2-I did not have
any cytotoxic effect on HT-29 cells at the tested doses. RVVA-PLA2-I at
a dose of 10 μg ml−1 (ﬁnal concentration of 172 nM) was not detri-
mental to HT-29 cells after 24 h of treatment (data not shown). In con-
trast, crude RVV at the same dose (10 μg ml−1) killedmore than 18% of
cells after 4 h of treatment and almost all the HT-29 cells were dead
after 24 h of treatment (data not shown). The inverted phase contrast
microscopic observation of RVVA-PLA2-I treated HT-29 cells did not re-
veal any gross morphological changes after 24 h of treatment (data not
shown). Analysis of cell membrane phospholipid hydrolysis revealed
that the RVVA-PLA2-I failed to hydrolyze the membrane phospholipids
of HT-29 cells after 4 h of treatment and about 350±19 μg (mean±
S.D., n=3) of FAs was released after 24 h of treatment. This suggests
that the amount of phospholipids hydrolyzed by RVVA-PLA2-I in treated
HT-29 cells was signiﬁcantly less (pb0.001) as compared to the phos-
pholipids hydrolyzed in themitochondrial and erythrocytemembranes.
3.5. In-vivo toxicity assay
Mortality or behavioural changes were not observed in mice after
48 h i.p. injection of RVVA-PLA2-I at a dose of 0.2 mg kg−1 body
weight. However, RVVA-PLA2-I prolonged the bleeding time and the
coagulation time of PPP in RVVA-PLA2-I treated mice as compared
to the control mice (data not shown). After the treatment of mice
with RVVA-PLA2-I, no changes were observed in WBC count. Never-
theless, there was a signiﬁcant decrease (pb0.01) in the RBC count
and the Hb content in the blood of treated mice as compared to theTable 4
Effect of RVVA-PLA2-I on different parameters of serum of albino mice. RVVA-PLA2-I (0.2 m
group of six BALB/c mice (n=6). Mice were sacriﬁced after 48 h of injection, blood was col
parameters. Values are mean±S.D. of six determinations.
Total protein (g/L) Glucose (g/L) CPK-MB (U/L) LDH (U/L) AL
Control 270.0±0.7 2.11±1.2 27.5±0.65 1281.5±0.9 27
Treated 180.5±0.5a 2.53±1.5 303.0±1.6a 1054.5±1.1a 79
Signiﬁcance of difference.
a pb0.001.control mice (data not shown) suggesting RVVA-PLA2-I caused lysis
of erythrocytes in in-vivo condition.
Table 4 shows the effect of RVVA-PLA2-I on serum parameters of
treated mice. Administration of RVVA-PLA2-I resulted in a signiﬁcant
increase (pb0.05) in serum enzymes such as ALP, CPK-MB, SGOT,
SGPT, and triglycerides. On the other hand, the serum level of LDH
was signiﬁcantly decreased in RVVA-PLA2-I treated mice as compared
to control. However, there was no change in the cholesterol and glu-
cose levels in the serum of RVVA-PLA2-I treated mice as compared to
control mice (Table 4).
4. Discussion
4.1. Correlation between catalytic activity and membrane damaging
activity of RVVA-PLA2-I
Lysis of artiﬁcial membranes by PLA2s from various snake venoms
e.g., Bothrops pirajai and Crotalus durissus terriﬁcus has been shown to
be independent of their enzymatic activity, since both native and cata-
lytically inactivated enzymes are fully able to disrupt membranes [19].
Conversely, we have presented contradictory evidences showing that
mitochondrial and erythrocyte membrane hydrolyzing properties of
Russell's viper acidic PLA2 (RVVA-PLA2-I) are dependent on its catalytic
activity which is similar to membrane damaging activity of PLA2 en-
zymes (NK-PLA2-I and NK-PLA2-II) isolated from Naja kaouthia venom
[5]. The current investigation shows that the differentmembranes stud-
ied in the present investigation have different structural organisations
as reﬂected by their distinctly different sensitivities towards RVVA-
PLA2-I. Nonetheless, this membrane damaging activity is dependent
on Ca2+ ion because in the presence of the metal chelator EDTA,
RVVA-PLA2-I lost itsmembrane damaging aswell as its catalytic activity
in a parallel manner. The degree of membrane phospholipid hydrolysis
increaseswith the increase in the pre-incubation time of themembranesg kg−1 body weight) dissolved in 0.1 ml of PBS was injected intraperitoneally into a
lected immediately by venipuncture and the serum was used for the assay of different
P (U/L) SGOT (U/L) SGPT (U/L) Cholesterol (g/L) Triglycerides (g/L)
.5±0.8 144.0±2.2 50.0±0.91 0.7±0.4 0.2±0.04
.3±1.2a 191.7±2.6a 135.0±1.4a 0.8±0.3 1.0±0.05a
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dependent on the catalytic activity of RVVA-PLA2-I.
The indirect haemolysis exhibited byRVVA-PLA2-Iwas due to the for-
mation of phospholipid hydrolysis products like lysophospholipids and
FAs from egg-yolk phospholipids/PC and these products caused further
damage to the membrane [20]. The same hypothesis can be put forward
to explain the enhanced susceptibility of the erythrocytes in the presence
of egg yolk phospholipids/PC and Ca2+, because amongst the tested
phospholipids, PC is the most favoured substrate for RVVA-PLA2-I for
binding followed by hydrolysis [15]. The spectroﬂurometric study has
also shown that the presence of Ca2+ enhanced the binding of
RVVA-PLA2-I with PC [15], conﬁrming this is a Ca2+-dependent PLA2.
Furthermore, inhibitor studies with speciﬁc amino acid modifying re-
agents, neutralization studies with polyvalent antivenom, and the
heat-inactivation data in the present study have suggested a correlation
between the catalytic andmembrane phospholipid hydrolysis properties
of RVVA-PLA2-I. However, there is enough controversy regarding the role
of enzymatic activity in the pharmacological effects of snake venomPLA2-
enzymes and it may be suggested that both enzymatic and non-
enzymatic processes have contributed in the pharmacological process
[5–8,15].
The heat-inactivation study also leads us to conclude that the binding
of RVVA-PLA2-I tomembrane PC followed by its hydrolysis is an essential
step for inducing membrane damage [5,8]; because, a parallel inhibition
of membrane PC binding, catalytic activity as well as membrane damage
in case of heat-inactivated RVVA-PLA2-I was observed owing to the fact
that heat treatment partially distorted PLA2 structure (Supplementary
Fig. S3). This partial unfolding of RVVA-PLA2-I could not be regained
after cooling (Saikia, D. and Mukherjee, A. K., unpublished observation)
resulting in a reduction in PC binding property and activity of heat-
denatured RVVA-PLA2-I.
4.2. Differential hydrolysis of mitochondrial and erythrocyte membrane
phospholipids: does it reﬂect the differences in PLA2-sensitive phospholipid
composition of biomembranes?
Membrane surface properties, including membrane ﬂuidity, cur-
vature, surface charge, and membrane-induced structural changes in
the enzyme, determine the strength of interaction, cooperatively of
membrane binding, and the extent of PLA2 activation [5,8]. Snake
venom PLA2 induced injury to mitochondria brings about a change
in the mitochondrial volume [5,21]. The preferential release of C16
to C18 FAs from the mitochondrial and erythrocyte membranes during
the initial phase of attack by RVVA-PLA2-I is correlated with its pref-
erence for short chain fatty acids at the sn-2 position. It is presumed
that even if PLA2 binds uniformly across the solid and ﬂuid domains
of membrane enriched in the long and short chain fatty acids respec-
tively, enzyme shows a preference for short chain fatty acids, which
are in ﬂuid phase [22]. This is due to the lower surface area density
of the lipid head groups in short chain fatty acids that are present in
ﬂuid phase [23].
Our previous study has shown that RVVA-PLA2-I preferentially hy-
drolyzes PC over PS and PE [15]. It is very interesting to observe that
RVVA-PLA2-I preferentially hydrolyzes the phospholipids of erythrocyte
membrane compared tomitochondrial membrane even though the lat-
ter possesses much greater percentage of PC on its outer leaﬂet (40.9%)
than the outer leaﬂet of the former membrane (19%) [24]. Therefore,
our result suggests that existence of signiﬁcantly greater number of
RVVA-PLA2-I sensitive regions in the erythrocyte membrane as com-
pared to the mitochondrial membrane might have a relevance to the
higher degree of phospholipid hydrolysis of the former membrane
[5,8]. These speciﬁc domains or venom PLA2 susceptible region(s)
may result from the presence of different fatty acids, more particularly
the short-chain fatty acids in these regions of themembrane. Therefore,
the presence of a large number of venom PLA2-sensitive phospholipid
compositions, rather than only PC content of that particularmembrane,maydetermine the extent ofmembrane damage induced by a particular
PLA2 [8].
Furthermore, RVVA-PLA2-I could hydrolyze the erythrocyte mem-
brane phospholipidswithin 15 min of incubationwhich is in sharp con-
trast to our previous observationwhere two phospholipase A2 enzymes
viz. NK-PLA2-I and NK-PLA2-II from N. kaouthia venom showed a lag
phase for binding with the erythrocyte membrane and subsequent
membrane hydrolysis [5]. Besides, N. kaouthia PLA2 enzymes preferen-
tially hydrolyze the membrane phospholipids of the mitochondria as
compared to that of the erythrocyte membranes [5]. It is interesting to
note that all these three PLA2s from snake venom have shown a prefer-
ence for hydrolyzing PC over PS or PE [5,13]; however, NK-PLA2-I and
NK-PLA2-II from N. kaouthia venom are basic in nature [5] whereas
RVVA-PLA2-I fromD. russelli venom is an acidic PLA2 enzyme. Therefore,
the differences in overall net charge in a venom PLA2 molecule may at-
tribute to differential binding and subsequent hydrolysis of phospho-
lipids of a particular membrane [12].
Evidence has been accumulating regarding the presence of nanome-
ter range small-scale structures and lipid domains in the lipid bilayer
and such organizational heterogeneity of lipid microdomains may
have structural and functional signiﬁcance [25–27]. The phospholipid-
binding domains with secondary binding sites for speciﬁc proteins are
well known, and this binding is often tightly regulated [28]. The differ-
ences in the membrane phospholipid hydrolysis by a venom PLA2 can
be supported by our previous observation that the phospholipid con-
stituents of microsomal membranes are less hydrolyzed as compared
to those of lysosomal membranes by the action of Vipera russelli
venom basic PLA2 [13,14]. Further, it has been suggested that PLA2
may be particularly active at domain interfaces which are the sites of
structural defects and hence good points of attack for these enzymes
[5]. The mechanism by which snake venom phospholipase A2 sensitive
phospholipid domains is formed in the mitochondrial or erythrocyte
membrane is not very clear. Although no adequate description of the
nature of such membrane lipid domains in terms of their abundance,
composition or dynamics has been provided; however, it may be as-
sumed that the physicochemical properties of individual phospholipids,
circumstantial effects of membrane proteins, phospholipid/cholesterol
ratio, and vitamin E content of the membrane contribute signiﬁcantly
to the formation of such domains [5,8,14,27].
The difference in the release of saturated and unsaturated fatty
acids from the membranes may be explained by the fact that in the
case of mitochondrial membrane, RVVA-PLA2-I preferentially binds
to one of the PLA2-sensitive domains of the membrane resulting in
quantitative increase in the release of fatty acids from that membrane
with respect to time [5]. In a contrast, RVVA-PLA2-I attacks different
phospholipid domains/region(s) of erythrocyte membrane and there-
fore, this kinetics of erythrocyte membrane phospholipid hydrolysis
favours the release of quantitatively as well as qualitatively different
FAs with respect to time. The ratio of saturated/unsaturated fatty
acids released from the erythrocyte membranemay lead us to assume
that during the initial phase of attack, RVVA-PLA2-I hydrolyzes a par-
ticular domain of erythrocyte membrane consisting of mostly the un-
saturated fatty acids. Slowly with an increase in time, the reaction
products build up which may help in PLA2 binding and in attacking
another domain of the same membrane enriched in more saturated
fatty acids rather than unsaturated fatty acids. Interestingly, this re-
sult contradicts with the ﬁnding of Shukla and Hanahan [12] showing
the acidic PLA2 puriﬁed from the venom of Agkistrodon halys blomhofﬁ
hydrolyzing only one domain of PC in intact erythrocytes. These dif-
ferences in erythrocyte membrane phospholipid hydrolysis pattern
of acidic PLA2s from two different snake venoms lead us to conclude
that not only the overall acidic charge, but also the charge at a partic-
ular region, known as interfacial binding surface (IBS) of PLA2 may
determine its competence for binding with different domains of a
membrane [29]. This reinforces the presence of venom PLA2-speciﬁc
sensitive regions in a particular membrane. It may be presumed that
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injected venom can induce greater damage to membranes and subse-
quent toxicity to the cells.
4.3. Why does RVVA-PLA2-I fail to hydrolyze HT-29 cell membrane
phospholipids?
The RVVA-PLA2-I at the tested dose (10 μg ml−1) did not show
any cytotoxicity against HT29 colon adenocarcinoma cells even
though PC is the most abundant phospholipids present in the outer
cell membrane of HT-29 cells [30]. Lomonte et al. [31] have shown
the cytotoxic effect of Myotoxin II from Bothrops asper on HT-29
cells at a dose of 50–100 μg ml−1 (micromolar range) whereas we
have examined the cytotoxicity at a dose of 10 μg ml−1 (nanomolar
concentration) to avoid any non-speciﬁc binding of PLA2 to cultured
cells [5]. Furthermore, considering the proportion of RVVA-PLA2-I
present in RVV, we did not perform cytotoxicity at a very high dose
of this PLA2. Amongst the tested membranes, the least hydrolysis of
HT-29 cells can again be explained on the basis that it is not the over-
all quantity of PC in a membrane but either the availability of PC in a
PLA2-sensitive membrane and/or physicochemical properties of a
membrane are the most important criteria in order to elicit the
RVVA-PLA2-I-induced membrane damage [8]. It has been observed
that some of the components of the membrane such as cholesterol/
phospholipid ratio and vitamin E (α-tocopherol) content may inﬂu-
ence its ﬂuidity which in turn modulates the activity of venom PLA2
enzymes [14,32].
4.4. The RVVA-PLA2-I is non-lethal but affects the liver and cardiac tissues
of experimental animals
RVVA-PLA2-I (at a dose of 0.2 mg kg−1 i.p.) does not show any
mortality to the mice even after 48 h of injection suggesting that it
is devoid of any lethal effects in mice. The RVVA-PLA2-I represents
0.1% (w/w) of total RVV protein [13] and on average an adult Russell's
viper may inject 225–250 mg of venom (total amount in a bite) to its
victim (personal communication fromMr. D. Mitra, in-charge, Calcut-
ta Snake Park, Kolkata). Therefore, a maximum of 0.2 to 0.25 mg of
RVVA-PLA2-I would be injected in a victim by the bite of an adult
Russell's viper and this dose corresponds to the nanomolar concen-
tration of RVVA-PLA2-I in the blood of an adult victim. Since RVVA-
PLA2-I was found to be non-toxic to mice at a much higher dose
than this, therefore, it may be suggested that the PLA2 under study
does not contribute to lethality of RVV. It is noteworthy to mention
that non-toxic PLA2 enzymes from snake venom demonstrating phos-
pholipid hydrolysis activity have been reported and the exact contri-
bution of these PLA2s in snake venom is poorly understood [16,33].
However, evidence has been presented from our laboratory to show
that non-covalent interaction of relatively non-toxic PLA2s from
N. kaouthia venom with that of weak neurotoxin like molecules
(kaouthitoxins) from the same venom resulted in marked synergism
to potentiate the cytotoxicity of PLA2–kaouthiotoxin complex without
altering the biological properties of PLA2 enzymes [19]. The proteome
analysis of D. russelli siamensis venom revealed the presence of com-
plex of PLA2 with other unidentiﬁed venom proteins [34]. Presence of
such PLA2-interacting component(s) from D. russelli russelli venom
remains to be elucidated.
Increase in the level of most of the tested enzymes in the serum of
RVVA-PLA2-I treated mice suggests that it might be affecting different
organs, particularly the liver and cardiac tissues of mice. Every living
cell contains its complement of enzymes, most of which are intracel-
lular and are released into the circulation only after breakdown of the
cell or impairment of its membrane post‐envenomation [2]. Elevated
CPK-MB level suggested damage to the skeletal muscle and is indica-
tive of myonecrosis, whereas increased SGOT, SGPT and ALP levels inthe serum of treated mice indicated damage to the liver tissues
reinforcing RVVA-PLA2-I targets cardiac and hepatic tissues.
5. Conclusion
In conclusion, RVVA-PLA2-I preferentially hydrolyzed phospholipids
of erythrocyte membranes compared to liver mitochondrial mem-
branes. Interestingly, this PLA2 could not hydrolyze HT-29 colon adeno-
carcinoma cell membrane phospholipids after 24 h of treatment
suggesting a differential mode of attack on membrane phospholipids
by RVVA-PLA2-I. The GC analysis of saturated/unsaturated fatty acid re-
lease pattern from intact mitochondrial and erythrocyte membranes
after the addition of RVVA-PLA2-I suggested the existence of a signiﬁ-
cantly greater number of RVVA-PLA2-I sensitive domains in the erythro-
cytemembraneas compared to themitochondrialmembrane. Although,
the exact nature of the membrane domain(s) responsible for binding
with this acidic PLA2 fromRussell's viper could not be identiﬁed; howev-
er, our study has provided enough evidences in support of membrane
domain hypothesis. Further studies to identify the nature of thesemem-
brane domains are in progress.
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